P&G: buys German Merck's consumer health business
(CercleFinance.com) - Procter & Gamble has signed an agreement to acquire the consumer health business of Germany's Merck for approximately 4.
2 billion dollars, the US giant said on Thursday.
P&G says the acquisition will expand its consumer healthcare portfolio, which already includes brands such as Vicks, Metamucil, Pepto-Bismol, Crest and Oral-B.
Merck's consumer health business includes over 900 products, such as Neurobion, Dolo-Neurobion, Femibion, Nasivin, Bion3, and Seven Seas, which are primarily sold in Europe, Latin America and Asia.
The acquisition scope will replace the successful PGT Healthcare joint venture P&G had with Teva Pharmaceutical, which will be terminated in July, the US company said.
P&G aims to close the deal by the end of 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
2 billion dollars, the US giant said on Thursday.
P&G says the acquisition will expand its consumer healthcare portfolio, which already includes brands such as Vicks, Metamucil, Pepto-Bismol, Crest and Oral-B.
Merck's consumer health business includes over 900 products, such as Neurobion, Dolo-Neurobion, Femibion, Nasivin, Bion3, and Seven Seas, which are primarily sold in Europe, Latin America and Asia.
The acquisition scope will replace the successful PGT Healthcare joint venture P&G had with Teva Pharmaceutical, which will be terminated in July, the US company said.
P&G aims to close the deal by the end of 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.